Piramal Pharma

212.25
+1.21
(0.57%)
Market Cap
28,139.00 Cr
EPS
0.14
PE Ratio
493.75
Dividend Yield
0.05 %
Industry
Healthcare
52 Week High
307.90
52 Week Low
136.10
PB Ratio
3.54
Debt to Equity
0.70
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
neutral
Piramal Pharma to Consider Q4 Results on May 146 days ago
Piramal Pharma Limited has announced that it will consider its fourth quarter (Q4) financial results on May 14. This indicates that the company is preparing to release its earnings report for the last quarter of the fiscal year, which is a standard practice for publicly traded companies.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,836.60
#1 4,40,661.86
37.20
#1 49,887.20
12.06
#1 9,648
13.77
62.24
6,124.50
1,62,586.23
78.35
8,184.00
0.89
1,600
#1 64.53
60.86
1,542.90
1,24,606.91
24.70
26,520.70
14.17
4,155
47.38
57.59
3,285.20
1,11,186.10
59.18
10,785.70
11.59
1,656
13.54
54.31
2,415.40
99,654.22
48.14
10,615.60
19.57
1,942
-16.38
46.37
1,171.30
97,739.76
#1 18.38
28,905.40
12.36
5,578
1.69
51.52
2,085.30
95,202.48
32.75
20,141.50
#1 19.94
1,936
38.82
54.25
892.50
89,806.38
19.65
19,831.50
13.82
3,831
29.92
53.95
1,242.00
72,135.56
19.97
29,559.20
17.55
3,169
-10.04
59.05
30,725.00
65,288.48
48.97
6,097.20
10.80
1,201
16.01
55.94

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
14.23 %
Net Income Growth
-109.54 %
Cash Flow Change
107.60 %
ROE
-108.36 %
ROCE
173.33 %
EBITDA Margin (Avg.)
40.67 %

Quarterly Financial Results

Quarterly Financials
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
1,345
1,612
1,709
2,229
1,574
1,777
1,814
2,196
1,802
1,980
2,034
2,591
1,993
2,320
2,233
Expenses
1,197
1,381
1,314
1,733
1,465
1,554
1,629
1,812
1,617
1,646
1,723
2,053
1,747
1,900
1,867
EBITDA
148
231
395
495
109
223
185
384
185
334
312
538
246
420
367
Operating Profit %
9 %
12 %
15 %
19 %
1 %
10 %
5 %
16 %
8 %
14 %
12 %
20 %
10 %
15 %
15 %
Depreciation
136
138
147
165
162
166
164
184
174
185
186
196
185
192
197
Interest
42
49
50
57
62
83
95
104
119
110
106
114
107
108
103
Profit Before Tax
-30
44
198
273
-115
-26
-74
95
-107
40
19
228
-45
120
67
Tax
-2
7
35
69
-6
11
17
45
-9
35
9
126
44
98
63
Net Profit
-28
37
163
204
-109
-37
-90
50
-99
5
10
101
-89
23
4
EPS in ₹
0.00
0.31
1.38
1.72
-0.92
-0.31
-0.76
0.42
-0.83
0.04
0.08
0.77
-0.67
0.17
0.03

Balance Sheet

Balance Sheet
2021
2022
2023
2024
Total Assets
10,900
12,797
14,523
15,312
Fixed Assets
6,106
6,879
7,469
7,990
Current Assets
3,649
4,067
4,836
5,465
Capital Work in Progress
627
1,172
1,419
1,116
Investments
123
267
639
385
Other Assets
4,045
4,478
4,996
5,821
Total Liabilities
10,900
12,797
14,523
15,312
Current Liabilities
2,490
3,033
3,843
4,369
Non Current Liabilities
2,805
3,067
3,906
3,031
Total Equity
5,605
6,697
6,774
7,911
Reserve & Surplus
4,610
5,511
5,580
6,588
Share Capital
995
1,186
1,193
1,323

Cash Flow

Cash Flow
2021
2022
2023
2024
Net Cash Flow
110
-177
-32
166
Investing Activities
-4,464
-1,737
-1,334
-416
Operating Activities
598
766
484
1,005
Financing Activities
3,977
794
818
-422

Share Holding

% Holding
Sept 2022
Oct 2022
Dec 2022
Mar 2023
Jun 2023
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
34.79 %
0.00 %
34.79 %
34.79 %
34.79 %
35.02 %
35.02 %
35.02 %
35.02 %
34.95 %
34.95 %
34.95 %
34.95 %
FIIs
20.00 %
0.00 %
20.00 %
20.00 %
20.00 %
18.04 %
32.37 %
32.51 %
30.59 %
31.42 %
31.73 %
31.68 %
31.49 %
DIIs
4.86 %
0.00 %
5.28 %
4.99 %
5.49 %
7.83 %
8.02 %
9.68 %
12.12 %
12.95 %
13.81 %
14.10 %
14.78 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.42 %
0.00 %
11.80 %
13.94 %
16.77 %
16.81 %
16.95 %
15.57 %
15.13 %
13.94 %
13.29 %
13.29 %
13.11 %
Others
32.92 %
100.00 %
28.14 %
26.29 %
22.95 %
22.30 %
7.64 %
7.22 %
7.14 %
6.74 %
6.22 %
5.98 %
5.66 %
No of Share Holders
1,79,957
1,79,948
2,29,960
2,41,359
2,77,270
2,95,773
2,97,225
2,92,312
2,97,996
3,06,398
3,59,751
4,18,442
4,32,843

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.11 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.84 0.00 0.05 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2025 214.95 211.04
28 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jan 2025 221.25 224.00
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Oct 2024 221.30 215.15
26 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Jul 2024 157.10 166.30
12 Jul 2024 DIVIDEND Dividend
₹ 0.11 /share
12 Jul 2024 148.05 151.60
02 Aug 2023 RIGHTS Rights
5:46
02 Aug 2023 101.95 103.86

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation11 hours ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation6 days ago
Board Meeting Intimation for Board Meeting Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)6 days ago
Announcement under Regulation 30 (LODR)-AcquisitionApr 23, 2025
Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Apr 01, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 20, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 19, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) -US FDA Inspection At Piramal PharmaS Facility Located At TurbhFeb 18, 2025
Intimation For Change In Domain Name And Generic E-Mail ID Of The Registrar And Share Transfer Agent (RTA) Of CompanyFeb 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 17, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Extension Of Timeline Communicated For Sale Of CompanyS Unit Situated At ThaneJan 31, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 29, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Issuance Of CorpJan 29, 2025
Integrated Filing (Financial)Jan 28, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 28, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJan 28, 2025
Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended 31St December 2024Jan 28, 2025
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited (Company) Held On 28Th January 2025Jan 28, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations)Jan 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 22, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Issuance Of CorpJan 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 13, 2025
Board Meeting Intimation for Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Jan 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 06, 2025
Intimation For Change In The Name Of The Registrar And Share Transfer Agent Of The CompanyJan 02, 2025
Intimation Regarding Change Of Name Of Registrar And Transfer Agent (RTA) Of The Company From Link Intime India Private Limited To MUFG Intime India Private LimitedJan 02, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')- Update On LitigationDec 06, 2024
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ('SEBI Listing Regulations')-Issuance Of Corporate GuaranteeNov 08, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 29, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptOct 26, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 24, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationOct 23, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 23, 2024
Unaudited Financial Results For Quarter And Half Year Ended 30Th September 2024Oct 23, 2024
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited ('Company') Held On 23Rd October, 2024Oct 23, 2024
Announcement under Regulation 30 (LODR)-Credit RatingOct 22, 2024
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ('SEBI Listing Regulations')Oct 21, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 14, 2024
Board Meeting Intimation for Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (''Listing Regulations'')Oct 14, 2024
Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ('SEBI Listing Regulations')Oct 10, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementOct 08, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 03, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 03, 2024

Technical Indicators

RSI(14)
Neutral
44.62
ATR(14)
Less Volatile
8.86
STOCH(9,6)
Oversold
16.20
STOCH RSI(14)
Oversold
4.25
MACD(12,26)
Bearish
-1.46
ADX(14)
Weak Trend
19.37
UO(9)
Bearish
36.67
ROC(12)
Downtrend And Accelerating
-4.62
WillR(14)
Oversold
-81.20

About Piramal Pharma

Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics (CHG) business, and an India Consumer Healthcare (ICH) business. Piramal Pharma Solutions provides integrated drug discovery, development, and manufacturing services. The company has a joint venture with Allergan in ophthalmology and a minority investment in Yapan Bio for biologics and vaccines. It is a leading player in India's self-care space with established brands. The company specializes in niche areas such as highly potent APIs, antibody drug conjugates, and biologics. In 2022, Piramal Pharma Limited was listed on the BSE and NSE following a demerger from Piramal Enterprises Limited.
Chairperson NameNandini Piramal